Roche heads to regulators with new autoimmune win for Gazyva
Continuing the reinvention of its cancer drug Gazyva as a treatment for immune-mediated diseases of the kidney—which resulted…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4…